x
ServiziMenu principaleHome
Home > Past events > ABC2 > Programme
Print

ABC2 Programme

Wednesday, November

10:00
Registration opens for individuals participants and for groups

Thursday, 7 November

  9:00
19:30
Exhibition
  9:00 Breast cancer patient advocacy session  
Introductions and greatest challenges in meeting the needs of patients with advanced breast cancer (Chairs: S. Knox, IT - K.A. Sabelko, US - F. Cardoso, PT) 
10:30  Coffee break
11:00 Breast cancer patient advocacy session
Challenges and guidelines in advanced breast cancer (Chairs: D. “CJ” M. Corneliussen-James, US and M. Morand, AU)
11:00 prIME Oncology Satellite symposium supported by Celgene Corporation
Innovation and differentiation:
Key components of successful strategies for management of advanced breast cancer
 
  • Welcome and introduction (A. Di Leo, IT)
  • Contemporary chemotherapy for advanced breast cancer (ABC): Have we hit a glass ceiling? 
    (A. Di Leo, IT)
  • Tailoring chemotherapy for selected breast cancer phenotypes: The scientific rationale 
    (G. Curigliano, IT)
  • Audience questions and faculty comments 
  • The current and potential future role of albumin-bound paclitaxel in ABC (J. Cortés, ES)
  • Audience questions and faculty comments 
  • Taking what we’ve learned from ABC into the neoadjuvant setting (M. Untch, DE)
  • Symposium pearls and concluding remarks (A. Di Leo, IT)
  Symposium faculty:

Angelo Di Leo, Istituto Toscano Tumori, Hospital of Prato, Prato, IT
Javier Cortés, Vall d’Hebron University Hospital, Barcelona, ES
Giuseppe Curigliano, European Institute of Oncology, Milan, IT
Michael Untch, Helios Klinikum Berlin-Buch, Berlin, DE
12:30 Lunch
13:30 Opening session (Chairs: F. Cardoso, PT - L. Norton, US)
13:30 Opening and introduction (Chair: F. Cardoso, PT)
 
  • Welcome to Lisbon (N. Cabral, President of the Port of Lisbon, PT)
  • Keynote lecture
    A personal journal through advanced breast cancer (D. Fenech, MT)
14:15 Major advances since ABC1 (Chair: E.P. Winer, US)
 
  • Advances in HER-positive advanced breast cancer (I.E. Krop, US
  • Advances in TN advanced breast cancer (G.W. Sledge, US)
  • Advances in endocrine therapy and endocrine resistance (M.J. Piccart, BE)
  • Advances in cytotoxic and other targeted therapy (J. Gligorov, FR)
  • Advances in imaging (N. Houssami, AU)
  • Discussion 
16:15 Coffee break
16:35 Best abstract presentations (Chair: F. Cardoso, PT)
 
  • Nursing and patient advocacy:
    The challenges in optimising care in patients with advanced breast cancer: Results of an international survey (S. McCutcheon, UK)   
  • Clinical issues:
    Overall survival and sequential treatment of patients with metastatic breast cancer treated by German office-based medical oncologists - Outcome data from the TMK Registry Group (N. Marschner, DE)
  • Clinical issues:
    Meta-analysis resolves the role of combination versus sequential chemotherapy for metastatic breast cancer (R. Dear, AU) 
  • Basic and translational research
    What we know about primary metastatic breast cancer: Pathological characteristics and outcome over a 10-year period  (J. Barinoff, DE)
17:30 ABC Award and Lecture: Deconstructing metastasis
(Chair: L. Norton, US - Awardee: J. Massagué, US)
18:00 Breast cancer patient advocacy session
How can the ABC guidelines address global challenges? (Chairs: M. Mayer, US and S. Mertz, US)
18:00 GlaxoSmithKline Satellite symposium
Integrating novel combinations into the sequencing of HER2-positive metastatic breast cancer treatment
 
  • Introduction
  • Progression beyond trastuzumab: Where are we now?
    (V. Guarneri, IT)
  • Biologic rationale and clinical evidence for using two anti-HER2 therapies with different modes of action (W. Janni, DE)
  • How to define the right sequence in the HER2-positive metastatic breast cancer scenario? Interactive case studies (E. Ciruelos, ES)
  • Discussion and closing remarks
  Symposium faculty

Valentina Guarneri, University of Padova, IRCSS, Padova, IT
Wolfgang Janni, University Hospital Ulm University of Ulm, Ulm, DE
Eva Ciruelos, Hospital Universitario 12 de Octubre, Madrid, ES
   
19:30 Welcome cocktail

Friday, 8 November

  9:00
19:30
Exhibition
 9:00 Inoperable locally advanced breast cancer (part I) (Chairs: F. Cardoso, PT - E.P. Winer, US)
 
  • The biology of locally advanced breast cancer: Inflammatory and non-inflammatory (F. Penault-Llorca, FR)
  • Epidemiology and geographic differences (E. Senkus-Konefka, PL) 
  • Systemic therapy: Optimal strategies and therapies (N. Harbeck, DE)
  • Discussion 
10:15 Coffee break
10:45 Inoperable locally  advanced breast cancer (part II) (Chairs: F. Cardoso, PT - E.P. Winer, US)
 
  • Radiotherapy: Best timing and techniques (C. Vrieling, CH)
  • Surgery: Challenges and opportunities (M.J. Cardoso, PT)
  • Discussion 
11:40   Specific populations (Chair: K. Gelmon, CA)
 
  • Metastatic male breast cancer (S.H. Giordano, US)
  • BRCA-related advanced breast cancer (P.A. Francis, AU)
  • Discussion 
12:30 Survivorship in advanced breast cancer 
Panel discussion
(Chair: K. Redmond, CH; Panelists: L. Fallowfield, UK - E. Bergsten Nordström, IT - M. Mayer, US - O. Pagani, CH - A.H. Partridge, US and N. West, UK)
13:00 Lunch and poster session (please see the list of poster presentations at the bottom of this page)
14:00 Specific metastatic sites (Chairs: F. André, FR - H.S. Rugo, US)
 
  • Multidisciplinary approach to liver metastases (C.H. Barrios, BR)
  • Update on brain metastases management (N.U. Lin, US)
  • Optimal management of pleural effusions (B. Kaufman, IL)
  • Chest wall recurrences and cutaneous metastases (K.L. Blackwell, US)
  • Can specific sites of metastases be predicted and prevented? (L. van 't Veer, US)
  • Discussion 
15:40      Special session (Chair: L. Norton, US)
 
  • The role of mathematical and computer modeling for metastases research (S.D. Merajver, US)
  • Discussion
16:00 Coffee break
16:30    Supportive and palliative care issues (Chairs: M.S. Aapro, CH and G.W. Sledge, US)
 
  • Optimal pain control (L. Biganzoli, IT)
  • Optimal management of nausea and vomiting (J. Bergh, SE)
  • Psycological support: When and how? (L. Fallowfield, UK)
  • Patient perspective on symptom control (M. Mayer, US)
  • Disparities in access to supportive/palliative specialised care (N.S. El Saghir, LB)
  • Discussion
18:00 Novartis Oncology Reception
18:30 Breast cancer patient advocacy - Meet the expert session
Where will we be in the coming years? (Chair: K. Redmond, CH; Panelists: L. Fallowfield, UK - L. Norton, US - A.H. Partridge, US - M.J. Piccart, BE )
18:30-
19:30
Novartis Oncology Satellite symposium
Advanced breast cancer cases - Packing for the journey
(Chair: W. Janni, DE)
 
  • Welcome aboard (W. Janni, DE)
  • Understanding the landscape of ABC (W. Janni, DE)
  • Mapping out treatment options in HR+/HER2- ABC 
    (G. Jerusalem, BE)
  • Maintaining quality of life and staying on course with therapy in HER+/HER2- ABC (M. Mano, BR)
  • Overall Q&A Panel
  • Conclusions and overview of the journeys ahead (W. Janni, DE).
  Symposium faculty

Wolfgang Janni, University of Ulm, Ulm, DE
Guy Jerusalem, Centre Hospitalier Universitaire, Liege, BE
Max Mano, University of Sao Paulo, Sao Paulo, BR

 

Saturday, 9 November

  9:00
13:00 
Exhibition
 9:00  Consensus session (Part I)
(ABC2 Chairs)
10:30 Coffee break 
11:00 Report from ABC Patient Advocacy Committee
(D.“CJ” M. Corneliussen-James, US)
11:15 Consensus session (Part II)
(ABC2 Chairs)
13:00  Close

A/V RECORDING DURING THE CONFERENCE IS PROHIBITED 

Poster session

Posters can be viewed from Thursday, 7 November, 11:00 hours till Saturday, 9 November at 13:00 hours.br> On Friday, 8 November, during the lunch break from 13:00 to 14:00 hours, the poster session will be held with the visit of the designated members of the faculty.

BP: Best poster presentation; PO: Poster presentation

 BP27 Count us, know us, join us global survey: Looking at quality of life issues affecting advanced breast cancer patients worldwide and the role of their caregivers. Shirley Mertz, US
 BP40 Multicenter phase II study of apatinib, a novel inhibitor of VEGFR, in heavily pretreated patients with metastatic triple negative breast cancer. Biyun Wang, CN
 BP41 Effectiveness of taxane- or anthracylin-based compared to taxane- and anthracyline-free first-line treatments of patients with metastatic breast cancer treated by German office-based medical oncologists. Data from the TMK Registry Group. Norbert Marschner, DE
 PO28 Defining the unique and persistent needs of young women in the U.S. living with metastatic breast cancer through a multi-phased needs assessment. Arin Hanson,US
 PO29 Metastatic breast cancer in Canada: The lived experience of patients and caregivers presented by the Canadian Breast Cancer Network. Niya Chari, CA
 PO30 Surveying young women with metastatic breast cancer to create interventions with impact. Jean Rowe, US
 PO31 Palliative care and metastatic breast cancer: Involvement of a community palliative care specialist nursing team. Maria Leadbeater, UK
 PO32 How do women with metastatic breast cancer view palliative care? A qualitative study using a grounded theory approach to enable the views of women to be sought. Tara Beaumont, UK
 PO33 Susan G. Komen® investment in metastatic breast cancer (MBC). Karen S. Durham, US 
 PO34  Funding priorities for cancer research in USA. An advocacy initiative to gauge perception of metastatic breast cancer research and funding amongst cancer researchers in the USA. Arti Santhanam, US                                        
 PO35 YSC research think tank:  Determining research priorities for young women with metastatic breast cancer. Jean Rowe, US
 PO36 Inflammatory breast cancer research foundation: Patient information and support, research collaboration and IBC bioBank. Ginny Mason, US
 PO37 Advanced breast cancer: Living in the moment. Never give up; even toward the end of life, a tiny flame of candle can give  still  warmth. Gloria Wei-Chieh Lin, TW
 PO38 A healthy walk with sticks in the midst of nature. Julia Lynn Fishwick, IT 
 PO42 Surgical management of primary tumor in newly diagnosed metastatic breast cancer patients - A systematic review of the literature. Felipe Ades, BE
 PO43 Role of breast surgery on survival of patients with primary advanced breast cancer. Iryna Liubota, UA
 PO44 Audit of the investigation and management of loco-regional breast cancer recurrences in a UK district general hospital. Alice Elvy, UK
 PO45 Surgical resection of the primary tumor may improve survival in patients with stage IV breast cancer. Kenji Higaki, JP    
 PO46    Pulmonary resection for lung oligometastatic disease in metastatic breast cancer. Mariko Kochi, JP
 PO47 Using local flaps for coverage of defects after excision of advanced malignant breast lesions. Mahmoud Alhussini, EG
 PO52  Are postchemotherapy target volume adequate as boost volume for conserved breast in locally advanced breast cancer? Sushma Agrawal, IN
 PO53  Clinical target volume in conserved breast in locally advanced breast cancer. Sushma Agrawal, IN
 PO54 Activity and duration of chemotherapy in different biologic subtypes in metastatic breast cancer patients. Matteo Lambertini, IT 
 PO55  The combination chemotherapy of gemcitabine and vinorelbine in HER2-negative patients with taxane-pretreated metastatic breast cancer: A phase II study of Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015 (UMIN000004839). Jun Yamamura, JP 
 PO56  Triple negative and hormone-negative/HER2-positive breast cancer: Which the worst for women with metastatic disease? A mono-institutional retrospective analysis on 460 patients. Raffaella Palumbo, IT
 PO57 Comparison of docetaxel plus trastuzumab and vinorelbine plus trastuzumab as first-line therapy of anthracycline pre-treated metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer (a sub-group analysis of the HERNATA study). Michael Andersson, DK   
 PO58 Efficacy and safety of first-line everolimus plus letrozole in ER+ HER2- metastatic breast cancer: A multi-center, open-label, phase 2 trial BOLERO-4. Francois Ringeisen, CH
 PO59 Efficacy and safety of everolimus plus exemestane combination therapy versus monotherapy with everolimus or capecitabine in HR+, HER2- breast cancer: A multi-center, open-label, phase 2 trial BOLERO-6. Guy Jerusalem, BE
 PO60 Good results of intensive systemic treatment of patients with HER2-positive breast cancer with brain metastases. Anna Niwinska, PL
 PO61 Oral vinorelbine and capecitabine: An acceptable and effective combination chemotherapy for early metastatic breast cancer (MBC). Martin Hogg, UK
 PO62 Different patterns of treatment with albumin-bounded paclitaxel (nab-paclitaxel) for targeted chemotherapy in metastatic breast cancer: A multicenter Italian experience on 125 women. Raffaella Palumbo, IT
 PO63 Impact of treatment with lapatinib in systemic advanced carcinoma breast. Manoj Behera, IN
 PO64 Comparison of fulvestrant versus tamoxifen for treatment advanced breast cancer in postmenopausal women. Charu Singh, IN
 PO65 The comparison of methotrexate and liposomal cytarabine in the  intrathecal treatment of patients with breast cancer and leptomeningeal metastasis. Anna Niwinska, PL
 PO66 All-oral combination chemotherapy with capecitabine and cyclophosphamide is effective and safe for metastatic breast cancer patients. Masahiko Suzuki, JP
 PO67 Clinical benefit of ethinylestradiol as a salvage endocrine therapy for the heavily pretreated-metastatic breast cancer. Hirotaka Iwase, JP
 PO68  Treatment with eribulin (Halaven) in heavily pre-treated patients with metastatic breast cancer. M Lynge, DK
 PO69 Eribulin in practice, review of 70 cases from single institute and comparison with Japan phase 2 study. Junichiro Watanabe, JP 
 PO70 Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer according to prior therapy. Carmine De Angelis, IT
 PO71  Safety profile and tolerability of trabectedin and indole-3-carbinol combination in refractory advanced breast cancer. Preliminary results of phase 1 clinical study. Richard Tancredi, IT 
 PO72 Clinical safety and efficacy of long-term use of zoledronic acid hydrate for breast cancer bone metastasis. Tomofumi Osako, JP  
 PO74 New trends in the survival of patients with locally advanced breast cancer. Nagi El Saghir, LB 
 PO75 Is the breast cancer graded prognostic assessment tool valid in Scottish patients with secondary brain metastases? Lucy Wells, UK
 PO76 Clinicopathological features and survival after recurrence in breast cancer patients with early and late recurrence after adjuvant chemotherapy. Byung Ho Son, KR
 PO77 Disease characteristics in HER2-positive metastatic breast cancer patients achieving complete remission during trastuzumab therapy. Snezana Susnjar, RS 
 PO79    Prolonged survival after breast cancer brain metastases (BCBM): Who has a chance? Zorica Tomasevic, RS
 PO80 Neutropenia may be a prediction marker of therapeutic effect in metastasis breast cancer patients treated with eribulin. Yuri Yoshimura, JP
 PO81 Electrochemotherapy of skin breast cancer metastases. Rodrigo Oom, PT
 PO82    Clinicopathological analysis of the risk factors of disease progression in HER2 positive breast cancer patients. Joanna Huszno, PL  
 PO83  Assessing acute thrombophlebitis due to intravenous vinorelbine chemotherapy in metastatic breast cancer patients at the University Hospital of North Staffordshire (UHNS). Shahid Gilani, UK 
 PO84 Visualizing treatment and outcomes in metastatic breast cancer. Gabrielle Rocque, USA  
 PO85 Characteristics and prognosis of hormone receptor positive and HER2 negative recurrent breast cancer patients receiving postoperative aromatase inhibitor. Ishida Mayumi, JP 
 PO86 Predictive markers of clinical outcome for breast cancer patients treated in phase 1 trials: National Cancer Center Hospital experience. Aiko Nagayama, JP
 PO87 Prognostic factors predicting survival after first recurrence in patients with metastatic breast cancer. Masahiro Hikichi, JP
 PO88 Locally advanced breast cancer in Albanian women. Elvisa Kozma, AL 
 PO89 Advanced breast cancer in Ethiopia: Characteristics and follow-up of 148 patients with stage 4 disease. Christoph Thomssen, DE  
 PO100 Long-term bone management by bisphosphonate in metastatic breast cancer patients. Junichiro Watanabe, JP 
 PO101 Management of peripheral neuropathy induced by nab-PTX therapy for breast cancer. Tsuyoshi Ohno, JP
 PO102 Paclitaxel induced CIPN - Can it be controlled? Rakesh Roy, IN
 PO103 Improving palliative care in clinical routine: Inhouse training of palliative medicine and its effects and evaluation in a breast and gynecological center of a CCC.  Rachel Wuerstlein, DE 
 PO104 Patients with discordance in estrogen receptor between primary breast cancers and recurrent tumors have poor outcomes. Sayuri Akiyoshi, JP 
 PO105 Changes in activities and participation resulting in disability associated with metastatic breast cancer. Ann Marie Potter, US
 PO106 Extended stability studies of anticancer drugs can improve the access of patients to innovative treatments. Example of eribulin in advanced/metastatic breast cancer. Alain Astier, FR
 PO107  Study of health resource utilisation in patients with HER2-positive metastatic breast cancer (SHRUB) – A prospective data collection study in progress. Jacinta Abraham, UK 
 PO108 Safety and efficacy of brachium implanted central venous access port for metastatic breast cancer patients. Tomomi Fujisawa, JP
 PO109 Use of whole body MRI in breast cancer: A retrospective analysis of WB-MRIs within a 12 month period in a cancer centre. Bhavi Trivedi, UK
 PO113 Discordance of hormone receptor and HER2 status between primary and recurrent breast cancer: New treatment strategy for predicting outcome of patients with breast cancer. Sho Shiino, JP
 PO115 Expression of androgen receptor in locally advanced breast cancer with special relation to various molecular phenotypes, clinicopathological factors and response to anterior chemotherapy in Indian women. Akshay Anand, IN
 PO116 Discordance in triple-receptor status between primary and recurrent breast cancer. Akiko Matsumoto, JP
 PO117 Impairment of IFN gamma production and NK cell cytotoxicity of advanced breast cancer patients. Sandra Radenkovic, RS  
 PO118 Significance of gene amplifications on relapse-free survival (RFS) and overall survival (OS) in metastatic breast cancer. Natasa Todorovic-Rakovic, RS 
 PO119 Immune reactivity at patient with breast cancer associated with type 2 diabetes mellitus. Natalia Botnariuc, MD 
 PO120 Factors, affecting changes in immunohistochemistry phenotype of breast cancer. Olexiy Aseyev, UA
 PO121 Increased relapse ratios in node-positive breast cancer patients with methylenetetrahydrofolate reductase polymorphism. Hakan Buyukhatipoglu, TR 
 PO122 Predictive factor of late recurrences in breast cancer patients. Hiromitsu Jinno, JP 
 PO123 Thymidylate synthase expression as a significant predictive factor in metastatic breast cancer. Hirohito Seki, JP 
 PO124 The influence of HER2 status on localization of the first relapse site in young HR-positive breast cancer patients treated with adjuvant ovarian ablation. Marijana Milovic-Kovacevic, RS 
 PO125 Influence of HER2 status on metastatic pattern in postmenopausal hormone receptor positive breast cancer patients treated with adjuvant tamoxifen only. Ivana Bozovic Spasojevic, RS

Consensus session

The Panel will update the ABC consensus recommendations for the management of advanced breast cancer continuing the work developed during ABC1.
The ABC2 consensus manuscript will be published after the meeting.